Anti-CD147 function blocking antibody (αCD147) therapy has been found not only to prevent neuronal and oligodendrocyte death in the acute phase after ischemic stroke, but also to profoundly protect white matter integrity and reduce brain atrophy and tissue loss in later stages (74). This evidence concerns the gene BSG and ischemic stroke.